Terms: = Leukemia AND PSA AND Treatment
46 results:
1. PIM Kinases as Potential Biomarkers and Therapeutic Targets in Inflammatory Arthritides.
Assirelli E; Ciaffi J; Scorcu V; Naldi S; Brusi V; Mancarella L; Lisi L; Pignatti F; Ursini F; Neri S
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542097
[TBL] [Abstract] [Full Text] [Related]
2. STAT3/LKB1 controls metastatic prostate cancer by regulating mTORC1/CREB pathway.
Pencik J; Philippe C; Schlederer M; Atas E; Pecoraro M; Grund-Gröschke S; Li WJ; Tracz A; Heidegger I; Lagger S; Trachtová K; Oberhuber M; Heitzer E; Aksoy O; Neubauer HA; Wingelhofer B; Orlova A; Witzeneder N; Dillinger T; Redl E; Greiner G; D'Andrea D; Östman JR; Tangermann S; Hermanova I; Schäfer G; Sternberg F; Pohl EE; Sternberg C; Varady A; Horvath J; Stoiber D; Malcolm TI; Turner SD; Parkes EE; Hantusch B; Egger G; Rose-John S; Poli V; Jain S; Armstrong CWD; Hoermann G; Goffin V; Aberger F; Moriggl R; Carracedo A; McKinney C; Kennedy RD; Klocker H; Speicher MR; Tang DG; Moazzami AA; Heery DM; Hacker M; Kenner L
Mol Cancer; 2023 Aug; 22(1):133. PubMed ID: 37573301
[TBL] [Abstract] [Full Text] [Related]
3. Prognostic value of neutrophil-to-lymphocyte ratio in patients with metastatic castration-resistant prostate cancer receiving prostate-specific membrane antigen targeted radionuclide therapy.
Stangl-Kremser J; Sun M; Ho B; Thomas J; Nauseef JT; Osborne JR; Molina A; Sternberg CN; Nanus DM; Bander NH; Tagawa S
Prostate; 2023 Oct; 83(14):1351-1357. PubMed ID: 37424145
[TBL] [Abstract] [Full Text] [Related]
4. Diagnostic Value of Magnetic Resonance Susceptibility-Weighted Imaging Scanning in Different Types of Early Prostate Cancer.
Gao R; Liu J; Zhu H
Scanning; 2022; 2022():4884646. PubMed ID: 35795617
[TBL] [Abstract] [Full Text] [Related]
5. Cost-Effectiveness of KTE-X19 for Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic leukemia in the United States.
Shah BD; Smith NJ; Feng C; Jeyakumar S; Castaigne JG; Faghmous I; Masouleh BK; Malone DC; Bishop MR
Adv Ther; 2022 Aug; 39(8):3678-3695. PubMed ID: 35727476
[TBL] [Abstract] [Full Text] [Related]
6. Cost-Effectiveness Analysis of Venetoclax in Combination with Azacitidine Versus Azacitidine Monotherapy in Patients with Acute Myeloid leukemia Who are Ineligible for Intensive Chemotherapy: From a US Third Party Payer Perspective.
Pratz KW; Chai X; Xie J; Yin L; Nie X; Montez M; Iantuono E; Downs L; Ma E
Pharmacoeconomics; 2022 Aug; 40(8):777-790. PubMed ID: 35696071
[TBL] [Abstract] [Full Text] [Related]
7.
Ye B; Zhou Y; Liu Y; Li X; Li T; Qi X
Anticancer Agents Med Chem; 2021; 21(7):919-926. PubMed ID: 32698748
[TBL] [Abstract] [Full Text] [Related]
8. Blinatumomab compared with standard of care for the treatment of adult patients with relapsed/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia.
Rambaldi A; Ribera JM; Kantarjian HM; Dombret H; Ottmann OG; Stein AS; Tuglus CA; Zhao X; Kim C; Martinelli G
Cancer; 2020 Jan; 126(2):304-310. PubMed ID: 31626339
[TBL] [Abstract] [Full Text] [Related]
9. Incidental Finding of Acute Lymphocytic leukemia in a Prostate-Specific Membrane Antigen PET/CT.
Acksteiner C; Sounness B
Clin Nucl Med; 2019 Sep; 44(9):e529-e531. PubMed ID: 31306192
[TBL] [Abstract] [Full Text] [Related]
10. Cost-effectiveness analysis of rasburicase over standard of care for the prevention and treatment of tumor lysis syndrome in children with hematologic malignancies in China.
Hu S; Han Y; Zhang W; Zhang T; Yao X; Liu L
J Med Econ; 2019 Aug; 22(8):742-750. PubMed ID: 30939962
[No Abstract] [Full Text] [Related]
11. Cost Effectiveness of Midostaurin in the treatment of Newly Diagnosed FLT3-Mutated Acute Myeloid leukemia in the United States.
Stein E; Xie J; Duchesneau E; Bhattacharyya S; Vudumula U; Ndife B; Bonifacio G; Guerin A; Li N; Joseph G
Pharmacoeconomics; 2019 Feb; 37(2):239-253. PubMed ID: 30382485
[TBL] [Abstract] [Full Text] [Related]
12. Tyrosine kinase inhibitor therapy prescribed for non-urologic diseases can modify psa titers in urology patients.
Sasaki T; Franco OE; Ohishi K; Filipovich Y; Ishii K; Crawford SE; Takahashi N; Katayama N; Sugimura Y; Hayward SW
Prostate; 2019 Feb; 79(3):259-264. PubMed ID: 30370673
[TBL] [Abstract] [Full Text] [Related]
13. Salvage Radiopeptide Therapy of Advanced Castrate-Resistant Prostate Cancer with Lutetium-177-Labeled Prostate-Specific Membrane Antigen: Efficacy and Safety in Routine Practice.
Kesavan M; Turner JH; Meyrick D; Yeo S; Cardaci G; Lenzo NP
Cancer Biother Radiopharm; 2018 Sep; 33(7):274-281. PubMed ID: 29989440
[TBL] [Abstract] [Full Text] [Related]
14. Cost-utility analysis of idelalisib in combination with rituximab in relapsed or refractory chronic lymphocytic leukaemia.
Casado LF; Hernández JÁ; Jarque I; Echave M; Casado MA; Castro A
Eur J Haematol; 2018 Mar; 100(3):264-272. PubMed ID: 29226472
[TBL] [Abstract] [Full Text] [Related]
15. Puromycin based inhibitors of aminopeptidases for the potential treatment of hematologic malignancies.
Singh R; Williams J; Vince R
Eur J Med Chem; 2017 Oct; 139():325-336. PubMed ID: 28803047
[TBL] [Abstract] [Full Text] [Related]
16. Synchronous mantle cell lymphoma and prostate adenocarcinoma-is it just a coincidence?
Petković I; Stojnev S; Krstić M; Pejčić I; Vrbić S
Vojnosanit Pregl; 2016 Nov; 73(11):1072-5. PubMed ID: 29341562
[TBL] [Abstract] [Full Text] [Related]
17. Pulsatilla saponin A induces differentiation in acute myeloid leukemia in vitro.
Wang T; Gong F; Zhang R; Cen J; Dai L; Zhu M; Qi X
Hematology; 2016 Apr; 21(3):182-6. PubMed ID: 26868262
[TBL] [Abstract] [Full Text] [Related]
18. Improved disease markers suggest dual response in a patient with metastatic castration resistant prostate cancer and chronic lymphocytic leukemia following active cellular immunotherapy.
Cheng HH; Soleau C; Yu EY
J Hematol Oncol; 2015 May; 8():51. PubMed ID: 25966929
[TBL] [Abstract] [Full Text] [Related]
19. Genotoxic and cytostatic effects of 6-pentadecyl salicylic anacardic acid in transformed cell lines and peripheral blood mononuclear cells.
Alam-Escamilla D; Estrada-Muñiz E; Solís-Villegas E; Elizondo G; Vega L
Mutat Res Genet Toxicol Environ Mutagen; 2015 Jan; 777():43-53. PubMed ID: 25726174
[TBL] [Abstract] [Full Text] [Related]
20. Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer.
Goldkorn A; Ely B; Quinn DI; Tangen CM; Fink LM; Xu T; Twardowski P; Van Veldhuizen PJ; Agarwal N; Carducci MA; Monk JP; Datar RH; Garzotto M; Mack PC; Lara P; Higano CS; Hussain M; Thompson IM; Cote RJ; Vogelzang NJ
J Clin Oncol; 2014 Apr; 32(11):1136-42. PubMed ID: 24616308
[TBL] [Abstract] [Full Text] [Related]
[Next]
